$0.50
(4.27%)
Add to watchlist
Create an alert
Stocks and Shares ISATrevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Company Information
About this company
Key people
Jennifer L. Good
President, Chief Executive Officer, Director
Thomas R. Sciascia
Co-Founder, Chief Scientific Officer
David C. Hastings
Chief Financial Officer
James V. Cassella
Chief Development Officer
Farrell Simon
Chief Commercial Officer
David P. Meeker
Independent Chairman of the Board
Dominick C. Colangelo
Independent Director
Michael Thomas Heffernan
Independent Director
Edward T. Mathers
Independent Director
Anne M. Vanlent
Independent Director
Click to see more
Key facts
- Shares in issue128.23m
- EPICTRVI
- ISINUS89532M1018
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$1.41bn
- Employees26
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.